

## CV OUTCOMES DATA INSIDE:

A FOURIER subanalysis of recent MI patients

FOR PATIENTS WHO HAVE RECENTLY SUFFERED AN MI,

*Add Repatha<sup>®</sup> today to help*

**PREVENT ANOTHER MI<sup>1</sup>**



### **INDICATIONS**

#### **Repatha<sup>®</sup> is indicated:**

- In adults with established cardiovascular disease to reduce the risk of myocardial infarction, stroke, and coronary revascularization
- As an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C)-lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH) to reduce LDL-C

### **IMPORTANT SAFETY INFORMATION**

- **Contraindication:** Repatha<sup>®</sup> is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha<sup>®</sup>. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha<sup>®</sup>.

Please see Important Safety Information throughout and click here for full [Prescribing Information](#).

 **Repatha<sup>®</sup>**  
(evolocumab) injection  
140 mg/mL

FOR PATIENTS WITH ESTABLISHED CVD,

# REPATHA® ADDED TO A STATIN *reduced the risk of composite CV events more than statins alone*<sup>2,3</sup>

Repatha® added to a statin was **proven to reduce the risk of composite CV events by 20% in a median of only 2.2 years of follow-up, and the benefit improved over time**<sup>3</sup>

FOURIER was a double-blind, randomized, placebo-controlled, event-driven trial in 27,564 adult patients with established cardiovascular disease and with LDL-C ≥70 mg/dL and/or non-HDL-C ≥100 mg/dL despite high- or moderate-intensity statin therapy. Patients received either subcutaneous injections of Repatha® (140 mg every 2 weeks or 420 mg once monthly) or placebo. On stable background lipid-lowering therapy, median LDL-C at baseline was 92 mg/dL.<sup>3</sup>



MI

27 %  
RRR<sup>3</sup>

- Primary composite endpoint of time to CV death, MI, hospitalization for unstable angina, stroke, or coronary revascularization: HR 0.85 (95% CI, 0.79-0.92;  $P < 0.0001$ )<sup>3</sup>

- **Stroke = 21% RRR<sup>3</sup>**

- Key secondary composite endpoint of time to CV death, MI, or stroke: HR 0.80 (95% CI, 0.73-0.88).<sup>3</sup>

- Relative risk reductions for the primary and secondary composite endpoints were driven by a reduction in the risk of MI: HR 0.73 (95% CI, 0.65-0.82), stroke: HR 0.79 (95% CI, 0.66-0.95), and coronary revascularization: HR 0.78 (95% CI, 0.71-0.86)<sup>3,\*</sup>

- **ARR of 2.0% in the overall Repatha® CV Outcomes Trial study population was evaluated at 36 months<sup>2</sup>**

- **Observed HR for CV death: 1.05 (95% CI, 0.88-1.25) and hospitalizations due to unstable angina: 0.99 (95% CI, 0.82-1.18)<sup>3</sup>**

\*Not statistically significant



Revascularization

22 %  
RRR<sup>3</sup>

## IMPORTANT SAFETY INFORMATION

- **Hypersensitivity Reactions:** Hypersensitivity reactions, including angioedema, have been reported in patients treated with Repatha®. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.
- **Adverse Reactions in Primary Hyperlipidemia:** The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.


From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. Hypersensitivity reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common hypersensitivity reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).

Please see Important Safety Information throughout and click here for full [Prescribing Information](#).

 **Repatha®**  
(evolocumab) injection  
140 mg/mL

Patients **WITHIN 1 YEAR** of their most recent MI are exposed to higher CV risk<sup>1,4,5</sup>

In a FOURIER subanalysis, **statin + Repatha®** provided greater ARR for patients who suffered an MI within 1 year compared to patients with a more distant MI<sup>1</sup>



For recent MI patients  
**ARR=3.2%**

For distant MI patients  
**ARR=1.3%**

**ARR of 2.0% in the overall Repatha® CV Outcomes Trial study population was evaluated at 36 months<sup>2</sup>**

- Analysis of 81% (N = 22,320) of patients in Repatha® CV Outcomes Trial with a prior MI<sup>1,2</sup>
- 5,711 patients who experienced an MI within 1 to 12 months of randomization were compared to 16,609 patients with a more distant MI (more than 12 months prior to randomization)<sup>1</sup>

**IMPORTANT SAFETY INFORMATION**

- **Adverse Reactions in the Cardiovascular Outcomes Trial:** The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: diabetes mellitus (8.8% Repatha®, 8.2% placebo), nasopharyngitis (7.8% Repatha®, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha®, 4.8% placebo). Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new-onset diabetes mellitus during the trial was 8.1% in patients treated with Repatha® compared with 7.7% in patients that received placebo.

Please see Important Safety Information throughout and click here for full [Prescribing Information](#).



# RECENT MI PATIENTS ARE COUNTING ON YOU



Patients **within 1 year** of their most recent MI are exposed to **higher CV risk**<sup>1,4,5</sup>



**Repatha® added to a statin** provided a **greater ARR** in patients who suffered a recent MI compared to those with a more distant MI.<sup>1</sup>



**For very high-risk\* patients who have suffered a recent MI,** ACC/AHA guidelines consider an LDL-C of 70 mg/dL or greater as the threshold to trigger action and recommend the addition of a PCSK9 inhibitor like Repatha® to further lower LDL-C and future CV risk.<sup>6\*</sup>



**THE TIME TO DO MORE IS NOW.**

**ADD REPATHA® today to help prevent a future MI.<sup>1</sup>**

\*Very high risk includes a history of multiple major ASCVD events or 1 major ASCVD event and multiple high-risk conditions.<sup>6</sup>

\*Class I: Add ezetimibe to maximal statin before adding a PCSK9 inhibitor; Class IIa: If on a clinically judged maximal LDL-C-lowering therapy and LDL-C  $\geq 70$  mg/dL, or non-HDL-C  $\geq 100$  mg/dL, adding a PCSK9 inhibitor is reasonable.<sup>6</sup>

## **IMPORTANT SAFETY INFORMATION**

• **Immunogenicity:** Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity with Repatha®.

**ACC/AHA**=American College of Cardiology/American Heart Association; **ARR**=absolute risk reduction; **ASCVD**=atherosclerotic cardiovascular disease; **CI**=confidence interval; **CV**=cardiovascular; **CVD**=cardiovascular disease; **HDL-C**=high-density lipoprotein cholesterol; **HR**=hazard ratio; **KM**=Kaplan-Meier; **LDL-C**=low-density lipoprotein cholesterol; **MI**=myocardial infarction; **PCSK9**=proprotein convertase subtilisin/kexin type 9; **RRR**=relative risk reduction.

**References:** **1.** Gencer B, Mach F, Murphy SA, et al. Evolocumab and cardiovascular outcomes in patients with recent myocardial infarction: analysis from FOURIER. Poster presented at: American Heart Association Scientific Sessions; November 16-18, 2019; Philadelphia, PA. **2.** Sabatine MS, Giugliano RP, Keech AC, et al; for FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med.* 2017;376:1713-1722. **3.** Repatha® (evolocumab) prescribing information, Amgen. **4.** Wang Y, Li J, Zheng X, et al. Risk factors associated with major cardiovascular events 1 year after acute myocardial infarction. *JAMA Netw Open.* 2018;1:e181079. doi:10.1001/jamanetworkopen.2018.1079 **5.** Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. *Eur Heart J.* 2015;36:1163-1170. **6.** Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol.* 2018: <https://doi.org/10.1016/j.jacc.2018.11.003>.

**Please see Important Safety Information throughout and click here for full [Prescribing Information](#).**

**AMGEN®**

Cardiovascular

© 2021 Amgen Inc.  
All rights reserved  
USA-145-82841 04/21

 **Repatha®**  
(evolocumab) injection  
140 mg/mL